Cytogam (Cytomegalovirus Immune Globulin Intravenous (Human)) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS:

Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as measles, mumps, and rubella; therefore, vaccination with live virus vaccines should be deferred until approximately three months after administration of CytoGam®. If such vaccinations were given shortly after CytoGam®, a revaccination may be necessary. Admixtures of CytoGam® with other drugs have not been evaluated. It is recommended that CytoGam® be administered separately from other drugs or medications which the patient may be receiving (see DOSAGE AND ADMINISTRATION section).

OVERDOSAGE

Although few data are available, clinical experience with other immunoglobulin preparations suggests that the major manifestations would be those related to volume overload.

CONTRAINDICATIONS

CytoGam® should not be used in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations. Persons with selective immunoglobulin A deficiency have the potential for developing antibodies to immunoglobulin A and could have anaphylactic reactions to subsequent administration of blood products that contain immunoglobulin A, including CytoGam®.

REFERENCES

1. Snydman DR, Mclver J, Leszczynski J, et al. A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 38:553-557, 1984.
2. Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. Transfusion; 25:516-522, 1985.
3. Snydman DR, Werner BG, Heinze-Lacey BH, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. NEJM 317:1049-1054, 1987.
4. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus Immune Globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Int Med 119:984-991, 1993.
5. Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus Immune Globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transplantation, 11:432-437, 1997.
6. Snydman DR, Werner BG, Tilney NL, et al. A final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: Comparison of randomized and open-label trials. Transplant Proceed 23:1357-1360, 1991.
7. Snydman DR, Werner BG, Dougherty NN, et al. A further analysis of the use of Cytomegalovirus Immune Globulin in orthotopic liver transplant patients at risk for primary infection. Transplant Proceed 26, suppl 1:23-27, 1994.
8. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. NEJM 326:1182-1186, 1992.
9. Ham JM, Shelden SR, Godkin RR, et al. Cytomegalovirus prophylaxis with ganciclovir, acyclovir and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant Proc; 27 (5 suppl 1):31-33, 1995.
10. Snydman DR. Combined CMV-IGIV and ganciclovir prophylaxis in CMV seronegative transplant recipients from CMV seropositive donors. Report on file, MedImmune, Inc.
11. Martin M. CMV prophylaxis with combination ganciclovir and CMV hyperimmune globulin followed by high-dose acyclovir in solid organ transplant recipients. Report on file, MedImmune, Inc.
12. Valantine H and Luikart H. Impact of CMV hyperimmune globulin on outcome after cardiothoracic transplantation: A comparative study of combined prophylaxis with CMVIG plus ganciclovir vs. ganciclovir alone. Report on file, MedImmune, Inc.
13. Bossell, et al. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR vol. 35:231-233, April 11, 1996.
14. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. Transfusion 26:210-213, 1986.
15. McIver J, Grady G. Immunoglobulin preparations. In: Churchill WH and Kurtz SR, (ed): Transfusion Medicine. Boston: Blackwell; 1988.
16. Schneider L, Geha R. Outbreak of Hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR vol. 43:505-509, 43:505-509, July 22, 1994.
17. Edwards CA, Piet MPJ, Chin S, et al. Tri(nButyl) phosphate detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 52:53-59, 1987.
18. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: A report of two cases and an analysis of the literature. J Am Soc Nephrology; 8: 1788-1793, 1997.
19. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis; 25: 228-234, 1995.
20. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose intravenous immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis; 28: 451-453, 1996.
21. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol.; 50:137-139, 1993.
22. Winward D and Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: Review of the literature and case report. Pharmacotherapy; 15(6): 765-772, 1995.
23. Phillips AO. Renal failure and intravenous immunoglobulin. Clin Nephrol; 37:217, 1992.
24. Lindberg HA, Wald MH, Barker MH. Renal changes following administration of hypertonic solutions. Arch Int. Med; 63:907-918, 1939.
25. Rigdon RH, and Cardwell ES. Renal lesions following the intravenous injection of a hypertonic solution of sucrose. Arch Int Med; 69:670-690, 1942.
26. Sekul E, Culper E, Dalaks M. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy; Frequency and risk factors. Ann Int Med; 121:259-262, 1994.
27. Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with aseptic meningitis. JAMA; 259:3269-3270, 1988.
28. Casteels Van Daele M, Wijndaele L, Hunnick, et al. Intravenous immunoglobulin and acute aseptic meningitis. NEJM; 323:614-615, 1990.
29. Scribner C, Kapit R, Philips E, et al. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med; 121:305-306, 1994.
30. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion; 26:410-412, 1986.
31. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G. Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood; 15:3789, 1993.
32. Reinhart WH, Berchtold PE. Effect of high dose intravenous immunoglobulin therapy on blood rheology. Lancet; 339:662-664, 1992.
33. Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J. Autoimmune; 13:129-135, 1999.
34. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion; 41:264-268, 2001.
35. Dalakas MC. High-dose intravenous Immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology, 44: 223-226, 1994.
36. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet; 2:217-218, 1986.
37. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J. Hematol; 65:30-34, 2000.
38. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev; 17:241-251, 2003.

For additional information concerning Cytomegalovirus Immune Globulin Intravenous (Human) contact:

Professional Services

MedImmune, Inc.

Gaithersburg, MD 20878, USA

1-800-949-3789

Manufactured by:

MASSACHUSETTS PUBLIC HEALTH

BIOLOGIC LABORATORIES

Boston, Massachusetts 02130, USA

US Govt. License No. 64

Revised January 2004

Marketed by:

MedImmune, Inc.

Gaithersburg, MD 20878, USA